Abstract:T his issue of ASSAY and Drug Development Technologies is dedicated to epigenetics, an emerging field whose potential is only beginning to be realized. From a mechanistic viewpoint, epigenetics is the science of post-translational modification of histone proteins and DNA through enzymes (‘‘writers’’ and ‘‘erasers’’) and the recognition of these changes by adaptor proteins (‘‘readers’’). Working in concert, these three classes function to control the access to DNA and, ultimately, gene expression. Of special interest is the regulation of gene expression in both healthy and disease states. This interplay between readers, writers, and erasers with chromatin is highly complex, and while progress has been made, much remains to be illuminated. However, it is clear that specific modifications and their enzymes are associated with disease, identifying potential therapeutic targets. As always, this requires the development of high-quality assays to faithfully recapitulate the biochemistry of these proteins with the goal of identifying viable starting points for small-molecule inhibitor development. At first glance, epigenetic enzymes (e.g., histone methyl transferases and demethylases) and histone adaptors (e.g., bromodomains) bear resemblance to other well-established classes of targets. In some cases, progress has been rapid such as for the BET bromodomain family of proteins, where several small-molecule inhibitors are in the clinic. Other epigenetic classes have proven to be more challenging. There are a number of challenges worth noting, but two obstacles stand out. First, epigenetic enzymes are not catalytically robust. Rather, they have evolved for sufficient, not maximal, turnover, manifesting as kcats measured on the order of minutes and, in some cases, hours. This also plays out at the cellular level where the dynamics of histone modifications are slow and sometimes occur over the course of days. Second, as novel targets, in many instances, high-quality potent compounds are not readily identified from screening. Given these constraints, robust well-designed assays and triage schemes must be implemented to identify validated chemical matter, which can then be advanced in terms of potency, selectivity, and DMPK properties to enter development. The articles in this issue highlight the challenges and creativity necessary to initiate the process through appropriately configured assays. The issue begins with an interview with David Allis, a leader in the field of epigenetics, who offers both his perspective of the early days and suggests what potential the future holds.

Crystal structure of bis(prop-2-yn-1-yl) 5-nitroisophthalate

Rehabilitative orbital decompression for Graves’ orbitopathy: results of a randomized clinical trial

In vitro macrophage colony formation by free lung cells during pulmonary injury.

Late orbital radiotherapy combined with intravenous methylprednisolone in the management of long-lasting active graves' orbitopathy: a case report and literature review

MR imaging in gastrointestinal emergencies.

Graves' Orbitopathy: Current Concepts for Medical Treatment

How Age Affects Graves’ Orbitopathy—A Tertiary Center Study

Temporal trends in the clinical presentation of Graves’ orbitopathy: a single–center retrospective study

[Graves' orbitopathy: Current concepts for medical treatment]

Epigenetic Drug Discovery: Great Potential and Significant Challenges.

Emergency Endoscopic Endonasal Optic Nerve Decompression for Graves' Orbitopathy

Animal identification. II. Freeze branding of seals for laboratory identification.

Long-term outcomes of inferomedial orbital wall decompression in Graves’ ophthalmopathy in an Asian population: A 30-year retrospective study

Long-term outcome of Graves' orbitopathy following treatment with sirolimus

Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy

Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience

Use of Rituximab After Orbital Decompression Surgery in Two Grave’s Ophthalmopathy Patients Progressing to Optic Neuropathy

[Surgical treatment of the sequelae of Basedow's ophthalmopathy]

Path-integral quantum cosmology. I. Vacuum Bianchi type I.

Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy

Interaction of surfactants with thickeners used in waterborne paints: a rheological study.